Riesgos y manejo de los sangrados con ACO | Titulo Master en Trombosis

Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors

[vc_row... Leer más →

Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study

Background: The safety and... Leer más →

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study

Objective: To determine... Leer más →

Idarucizumab for Dabigatran Reversal

[vc_tta_section i_icon_fontawesome="fa... Leer más →

Antidotes for novel oral anticoagulants: current status and future potential

The direct thrombin inhibitor dabigatran and the anti-Xa agents rivaroxaban, edoxaban,... Leer más →

Reversal of Vitamin K Antagonist (VKA) effect in patients with severe bleeding: a French multicenter observational study (Optiplex) assessing the use of Prothrombin Complex Concentrate (PCC) in current clinical practice

Introduction: Prothrombin Complex... Leer más →